NeutriSci Provides Update and Partner Progress
VANCOUVER, BC, Feb. 3, 2022 /CNW/ – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV: NU) (OTC PINK: NRXCF) (FRANKFURT: 1N9), an innovative technology company developing products, licencing, IP and technology for B2B partnerships and the nutraceutical industry, is pleased to provide the following update.
Tabletz: On January 17th, the Company shipped an order for 45,000 sticks to Tabletz for distribution in Japan. The product was received by Tabletzs’ distribution partner CFC Japan Co. for further distribution across the country to a national grocery chain, some convenience stores and to replenish product in the Biopole stores. While some shipping challenges remain, for the most part, the Company has overcome those challenges and is positioned nicely for future shipments to Japan. The Company is working on completing an additional order to replenish the existing stores as well building product for new stores to come online. Tabletz is implementing a comprehensive marketing campaign in Japan that includes social media, traditional media, in-store programs, and sampling programs where Covid restrictions allow. The next order is expected to ship in Q2. Further details on distribution partners, marketing initiatives and stores will follow.
Cryopharm: Cryopharm’s partner, Red Bud Roots, has completed manufacturing and started the distribution and sale of a small introductory order of products that initially includes gummies, to the market. Red Bud has distribution in 275 locations. They own licences for infusion, grow, extraction, sales and distribution. NeutriSci is expected to realize revenue from its licencing arrangement with Cryopharm in Q2 of this year. Cryopharm also continues to move forward with their partnership with an Oklahoma group. They have been working on supporting roll out needs and will continue to do so well into Q3. Timing for start of production is still unknown at this time.
Neuenergy: NeutriSci’s latest production of tablets for the neuenergy® line has made its way to its national distribution partner, ANB. The initial 1,500 case order will be placed into ANB’s distribution channel in Canada. Retailers include Overwaitea, Mckesson, Sobey’s, Safeway, Pharmasave, and Guardian. The previously announced partnership and order with the German marketing and distribution group, THIC, is on track to commence distribution of neuenergy® in the European market in Q2. An initial order for 10,000 units of resealable bulk bags with 36 tablets each has already been placed and a deposit has been received. The Company and THIC plan to release packaging, distribution and sales details in the coming weeks.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE NeutriSci International Inc.
For further information: For investor inquiries, please contact firstname.lastname@example.org